Literature DB >> 21376242

Horizons in therapy for corneal angiogenesis.

Surekha Maddula1, Don K Davis, Soumya Maddula, Michael K Burrow, Balamurali K Ambati.   

Abstract

Corneal neovascularization can lead to a devastating disease process that involves the breakdown of the limbal barrier and the formation of blood vessels in the cornea, leading to severe visual impairment. This review discusses the delicate balance between antiangiogenic and angiogenic factors that govern the antiangiogenic privilege of the cornea. Current treatment methods, clinical trials, and future prospects in the management of corneal neovascularization also are discussed.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21376242      PMCID： PMC4107641          DOI： 10.1016/j.ophtha.2011.01.041

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


  39 in total

1.  Photodynamic therapy for corneal neovascularisation and lipid degeneration.

Authors:  B J Brooks; B K Ambati; D M Marcus; A Ratanasit
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Authors:  Claus Cursiefen; Lu Chen; Magali Saint-Geniez; Pedram Hamrah; Yiping Jin; Saadia Rashid; Bronislaw Pytowski; Kris Persaud; Yan Wu; J Wayne Streilein; Reza Dana
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

3.  Inhibitory effect of triamcinolone acetonide on corneal neovascularization.

Authors:  Masatoshi Murata; Shinji Shimizu; Saburo Horiuchi; Masayuki Taira
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-26       Impact factor: 3.117

4.  Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model.

Authors:  Junichi Ideno; Hiroaki Mizukami; Akihiro Kakehashi; Yuka Saito; Takashi Okada; Masashi Urabe; Akihiro Kume; Masatoshi Kuroki; Masanobu Kawakami; Shun Ishibashi; Keiya Ozawa
Journal:  Int J Mol Med       Date:  2007-01       Impact factor: 4.101

5.  Corneal avascularity is due to soluble VEGF receptor-1.

Authors:  Balamurali K Ambati; Miho Nozaki; Nirbhai Singh; Atsunobu Takeda; Pooja D Jani; Tushar Suthar; Romulo J C Albuquerque; Elizabeth Richter; Eiji Sakurai; Michael T Newcomb; Mark E Kleinman; Ruth B Caldwell; Qing Lin; Yuichiro Ogura; Angela Orecchia; Don A Samuelson; Dalen W Agnew; Judy St Leger; W Richard Green; Parameshwar J Mahasreshti; David T Curiel; Donna Kwan; Helene Marsh; Sakae Ikeda; Lucy J Leiper; J Martin Collinson; Sasha Bogdanovich; Tejvir S Khurana; Masabumi Shibuya; Megan E Baldwin; Napoleone Ferrara; Hans-Peter Gerber; Sandro De Falco; Jassir Witta; Judit Z Baffi; Brian J Raisler; Jayakrishna Ambati
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

6.  1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor.

Authors:  R Riachy; B Vandewalle; E Moerman; S Belaich; B Lukowiak; V Gmyr; G Muharram; J Kerr Conte; F Pattou
Journal:  Apoptosis       Date:  2006-02       Impact factor: 4.677

7.  Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys.

Authors:  Chooi-May Lai; Wei-Yong Shen; Meliha Brankov; Yvonne K Y Lai; Nigel L Barnett; Shu-Yen Lee; Ian Y S Yeo; Ranjana Mathur; Joseph E S Ho; Paul Pineda; Amutha Barathi; Chong-Lye Ang; Ian J Constable; Elizabeth P Rakoczy
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

8.  Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats.

Authors:  J L Bourges; F Lallemand; E Agla; K Besseghir; J M Dumont; D BenEzra; R Gurny; F Behar-Cohen
Journal:  Mol Vis       Date:  2006-12-02       Impact factor: 2.367

9.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

10.  Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether.

Authors:  John D Sheppard; Randy J Epstein; Frank A Lattanzio; Domenica Marcantonio; Patricia B Williams
Journal:  Am J Ophthalmol       Date:  2006-03       Impact factor: 5.258
View more
  23 in total

1.  Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea.

Authors:  Paula Urquhart; Jenny Wang; David F Woodward; Anna Nicolaou
Journal:  J Lipid Res       Date:  2015-05-31       Impact factor: 5.922

2.  Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.

Authors:  Yoo C Kim; Hans E Grossniklaus; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

3.  Anti-neovascular effect of chondrocyte-derived extracellular matrix on corneal alkaline burns in rabbits.

Authors:  Hye Sook Lee; Ji Hyun Lee; Chae Eun Kim; Jae Wook Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-01       Impact factor: 3.117

Review 4.  Update on Herpes simplex keratitis management.

Authors:  Daniel Sibley; Daniel F P Larkin
Journal:  Eye (Lond)       Date:  2020-08-25       Impact factor: 3.775

5.  Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization.

Authors:  Jia Yin; Deborah S Jacobs
Journal:  Ocul Surf       Date:  2018-11-20       Impact factor: 5.033

6.  Vascular endothelial growth factor receptor 1 morpholino decreases angiogenesis in a murine corneal suture model.

Authors:  Yang Kyung Cho; Hironori Uehara; Jason R Young; Bonnie Archer; Xiaohui Zhang; Balamurali K Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-13       Impact factor: 4.799

Review 7.  Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea.

Authors:  Lulia Koujah; Rahul K Suryawanshi; Deepak Shukla
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

Review 8.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

9.  Activation of ocular surface mast cells promotes corneal neovascularization.

Authors:  WonKyung Cho; Sharad K Mittal; Elsayed Elbasiony; Sunil K Chauhan
Journal:  Ocul Surf       Date:  2020-09-08       Impact factor: 5.033

10.  The semaphorin 3A inhibitor SM-345431 accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model.

Authors:  Masahiro Omoto; Satoru Yoshida; Hideyuki Miyashita; Tetsuya Kawakita; Kenji Yoshida; Akiyoshi Kishino; Toru Kimura; Shinsuke Shibata; Kazuo Tsubota; Hideyuki Okano; Shigeto Shimmura
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.